Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 7
Opinion
Video
Emerging Immunotherapies in NMIBC
Author(s):
Panelists discuss how PD-L1 inhibitors such as durvalumab and sasanlimab represent a promising frontier in non–muscle-invasive bladder cancer (NMIBC) treatment. These immunotherapies work by unleashing the body’s immune response against cancer cells, potentially offering new options for patients whose disease doesn’t respond to conventional therapies such as BCG. Their ongoing phase 3 trials could establish immunotherapy as a valuable addition to the NMIBC treatment landscape.
Video content above is prompted by the following:
- Discuss PD-L1 inhibitors durvalumab and sasanlimab, which are currently in phase 3 trials for NMIBC. How do you see immunotherapies contributing to the treatment of NMIBC?
Related Videos
Related Content
